Indicated for: pulmonary arterial hypertension
Route of administration: oral
Substance: sitaxentan (antihypertensive)
ATC: C02KX03 (Cardiovascular system | Other antihypertensives | Antihypertensives for pulmonary arterial hypertension)
Sitaxentan is a selective endothelin receptor A antagonist used in the treatment of pulmonary arterial hypertension (PAH). It works by blocking the vasoconstrictive and proliferative effects of endothelin-1, a mediator involved in the pathogenesis of PAH, thereby reducing pulmonary arterial pressure and improving cardiac function.
Sitaxentan is administered orally, usually once daily, and is indicated for patients with WHO functional class II or III PAH. Treatment can lead to an increase in exercise capacity and improvement in symptoms such as dyspnea and fatigue.
Common side effects include headache, nausea, nasal congestion, and elevated liver enzymes. In rare cases, severe adverse reactions such as hepatotoxicity may occur. Regular monitoring of liver function is essential during treatment.
Sitaxentan is a valuable therapeutic option for patients with pulmonary arterial hypertension, contributing to improved quality of life and reduced disease progression.